Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: An eastern cooperative oncology group (ECOG) study

Keyphrases

• High Dose 100%
• Phase I Trial 100%
• Reperfusion 100%
• Solid Tumors 100%
• Eastern Cooperative Oncology Group 100%
• Group Studies 100%
• Bone Marrow Mononuclear Cells 100%
• Etoposide 100%
• High-dose Melphalan 100%
• Breast Cancer 60%
• Melphalan 60%
• Marrow 40%
• Consecutive Days 40%
• Colorectal Cancer 40%
• Relapsed or Refractory 40%
• Mucositis 40%
• Chemotherapy 20%
• Phase I Study 20%
• Platelets 20%
• Neutrophils 20%
• Dose Level 20%
• Ovarian Cancer 20%
• Melanoma 20%
• Fever 20%
• Transfusion 20%
• Treatment Toxicity 20%
• Diarrhea 20%
• Chemotherapy Regimen 20%
• Malignant Melanoma 20%
• Granulocyte Colony-stimulating Factor (G-CSF) 20%
• Antineoplastic Agents 20%
• High-dose Chemotherapy 20%
• Pancytopenia 20%
• Nausea-vomiting 20%
• Complete Response 20%
• Partial Response 20%
• Small Cell Lung Cancer 20%
• Common Toxicity Criteria 20%
• Dose-limiting Toxicity 20%
• Maximum Tolerated 20%
• Hepatic Dysfunction 20%
• Esophagitis 20%
• G-CSF Therapy 20%

Medicine and Dentistry

• Drug Megadose 100%
• Infusion 100%
• Solid Malignant Neoplasm 100%
• Melphalan 100%
• Phase I Trials 100%
• Oncology 100%
• Etoposide 100%
• Breast Cancer 50%
• Mucositis 33%
• Infection 33%
• Colorectal Carcinoma 33%
• Melanoma 33%
• Chemotherapy 16%
• Granulocyte Colony Stimulating Factor 16%
• Platelet 16%
• Nausea 16%
• High Dose Chemotherapy 16%
• Granulocyte Macrophage Colony Stimulating Factor 16%
• Chemotherapy Regimens 16%
• Diarrhea 16%
• Ovarian Cancer 16%
• Antineoplastic Activity 16%
• Liver Dysfunction 16%
• Esophagitis 16%
• Small Cell Lung Cancer 16%
• Pancytopenia 16%
• Neutrophil 16%
• Arsphenamine 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Phase I Trials 100%
• Etoposide 100%
• Solid Malignant Neoplasm 100%
• Melphalan 100%
• Breast Cancer 60%
• Infection 40%
• Melanoma 40%
• Mucosa Inflammation 40%
• Colorectal Carcinoma 40%
• Arsphenamine 20%
• Chemotherapy 20%
• High Dose Chemotherapy 20%
• Anticarcinogen 20%
• Ovary Cancer 20%
• Chemotherapy Regimens 20%
• Diarrhea 20%
• Nausea 20%
• Liver Dysfunction 20%
• Esophagitis 20%
• Granulocyte Colony Stimulating Factor 20%
• Granulocyte Macrophage Colony Stimulating Factor 20%
• Small Cell Lung Cancer 20%
• Pancytopenia 20%